Neurocrine Biosciences | NBIX - Passività Correnti





Passività Correnti Cambiamento Data
AbbVie USD 41.64B 458M 2026-06
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
Agios Pharmaceuticals USD 70.22M 11.37M 2026-06
ALKERMES USD 662.09M 62.59M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Amgen USD 25.5B 547M 2026-06
Biogen USD 3.92B 918.2M 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Cytokinetics USD 181.43M 17.76M 2026-06
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Exelixis USD 361.93M 9.05M 2026-06
Gilead Sciences USD 11.02B 1.54B 2026-06
Halozyme Therapeutics USD 344.44M 18.77M 2026-06
Incyte USD 1.31B 177.55M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Prothena USD 11.66M 20.86M 2026-06
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Repligen USD 132.66M 6.45M 2026-06
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
Teva Pharmaceutical Industries USD 15.65B 2.11B 2026-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06